BIIB Dividend History & Analysis | Yield
BIIB has a dividend yield of and paid per share in the last 12M. Complete payout history, full analyses and peer comparison.
Top Dividend Payers in Biotechnology
| SYMBOL | MARKET CAP USD | YIELD TTM | YIELD ON COST 5y |
|---|---|---|---|
| NOVO-B CO Novo Nordisk |
222,417 M | 4.57% | 4.77% |
| ABBV NYSE AbbVie |
461,257 M | 3.21% | 6.91% |
| GILD NASDAQ Gilead Sciences |
162,981 M | 2.56% | 5.68% |
| AMGN NASDAQ Amgen |
201,932 M | 2.96% | 4.69% |
| AZN ST AstraZeneca |
296,347 M | 1.74% | 3.13% |
| HLN NYSE Haleon |
43,333 M | 1.93% | 2.69% |
| PHM MC Pharma Mar S.A. |
1,630 M | 1.23% | 1.35% |
| BIOA-B ST BioArctic (publ) |
2,960 M | 0.59% | 1.40% |
| ALK-B CO ALK-Abelló |
8,251 M | 0.75% | 1.07% |
| REGN NASDAQ Regeneron Pharmaceuticals |
68,593 M | 0.54% | 0.64% |
| SYMBOL | MARKET CAP USD | GROWTH RATE | CONSISTENCY |
|---|---|---|---|
| NOVO-B CO Novo Nordisk |
222,417 M | 26.23% | 100.0% |
| HLN NYSE Haleon |
43,333 M | 21.48% | 100.0% |
| PHM MC Pharma Mar S.A. |
1,630 M | 18.62% | 99.0% |
| AMGN NASDAQ Amgen |
201,932 M | 7.02% | 100.0% |
| ABBV NYSE AbbVie |
461,257 M | 5.31% | 100.0% |
| GILD NASDAQ Gilead Sciences |
162,981 M | 2.74% | 100.0% |
| REGN NASDAQ Regeneron Pharmaceuticals |
68,593 M | 6.24% | 100.0% |
| AZN ST AstraZeneca |
296,347 M | 3.77% | 100.0% |
BIIB Dividend History
Dividend Monthly Return EX date, 0 years of data
Average monthly dividend return by ex-dividend date. The score below shows reliability based on how consistently dividends were paid in that month.
BIIB Dividend FAQ
As of July 2026, BIIB's dividend yield is %. This is calculated by dividing the trailing 12-month dividend rate (TTM rate) of - by the current share price of 198.91.
As of July 2026 BIIB does not pay a dividend.
Over the last 12 months, BIIB has issued dividend payments.
Based on historical data, the forecasted dividends per share for BIIB for the next payments are between 0 (+0.0%) and 0 (+0.0%). This suggests the dividend will remain relatively stable. The expected Yield for the next 12 months is about -%.
The next Ex-Dividend date for Biogen (BIIB) is currently unknown.
The next Ex-Dividend date for Biogen (BIIB) is currently unknown. We automatically update the next Ex-Dividend date when it is announced.
BIIB's average dividend growth rate over the past 5 years is -% per year.
BIIB's 5-Year Yield on Cost is -%. If you bought BIIB's shares at 349.04 five years ago, your current annual dividend income (- per share, trailing 12 months) equals -% of your original purchase price.
BIIB Payout Consistency is 0.0%. The payout consistency is a proprietary measure of how consistently a company has paid dividends over its lifetime and blends growth rate, number of dividend payments, interruptions or lowering dividends into one number.
BIIB's % Dividend Yield is considered as unknown.
The Dividend Payout Ratio of BIIB is unknown.
BIIB's Overall Dividend Rating is (unknown). Ratings surpassing 65% are regarded as acceptable, exceeding 75% are favorable and surpassing 85% are strong.
BIIB Outstanding Shares Analysis
Key Metric Definitions
Annual dividend per share divided by current share price.
Percentage of earnings paid as dividends. Below 60% = safe, above 100% = unsustainable.
Percentage of Free Cash Flow paid as dividends. More reliable than Payout Ratio since it measures actual cash.
Compound annual growth rate of dividends over the last 5 years.
Reliability of dividend payments over lifetime. Penalizes cuts and pauses.
Your effective yield if you bought 5 years ago. Shows dividend growth impact over time.
Consecutive years of dividend payments. 25+ years = Dividend Aristocrat.
Proprietary score (0-100) combining yield, growth, safety and consistency.
Last update: 2026-07-09 02:38 UTC